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Poster Session I 61transplant to relapse was 466 days (range 182–729) for the ALL
group, and 2270 days (range 130–4410) for the AML/MDS group.
The primary cause of death was disease recurrence (n 5 11), three
ALL and eight AML/MDS patients. Three patients died of acute
GVHD, 2 from infection, and for one AML/MDS patient a specific
cause of death was not known. These data show that even when re-
lapse after a first HCT occurs, nearly 1/3 of pediatric patients with
acute leukemia may still be salvaged with a second HCT.162
EVALUATION OF A POWERED INTRAOSSEOUS DEVICE FOR BONE MAR-
ROW SAMPLING
Cohen, S.C., Soroka, J.M. Cancer Care Center of South Texas, San An-
tonio, TX.
The importance of bone marrow examination in the evaluation of
leukemia, multiple myeloma, anemia, pancytopenia, and other dis-
orders is well established. The objective for this study was to evalu-
ate the ability of a powered bone marrow aspiration device to
penetrate the intraosseous medullary space of the iliac crest, and
to aspirate bone marrow samples for the ultimate purpose of diag-
nosing disease and monitoring the course of disease and medical
therapy. The device was used to obtain bone marrow samples in ac-
cordance with accepted practice guidelines and device’s directions
for use. Among other data, insertion success, time to insertion,
and complications were recorded. Patient pain levels were rated
from 0 to 10 (105extreme pain). Device operators rated the use
of the device from 0 to 10 (105outstanding). There were 55 patients
in the study from three centers. Successful insertion and aspiration
of bone marrow samples were achieved in 54 of the 55 patients
(98.1%). Mean insertion time was 4.9 6 3.0 seconds; significantly
faster than the 7.3 minutes reported by Kuball et al* (one-sample
t-test, p\ 0.001). There were no complications. The mean inser-
tion pain score was 2.5 6 2.2 and the mean aspiration pain score
was 3.7 6 2.5. On a scale of 0 to 10, the six operators rated the
ease of use of the device at a mean score of 8.36 1.7. Findings sug-
gest that the powered aspiration device is safe and effective for bone
marrow aspirations; and that through the use of powered device,
needle placement time can be reduced—thereby reducing patient
pain.
* Kuball J, Schu¨z J, Gamm H, Weber M. Bone marrow punctures
and pain. Acute Pain 2004;6(1):9–14.163
CLOFARABINE PRE-CONDITIONING PRIOR TO ALLOGENEIC STEM CELL
TRANSPLANTATION IN HIGH RISK ACUTE MYELOID LEUKAEMIA (AML):
A WELL TOLERATED REGIMEN WITH BOTH FULL AND REDUCED TOX-
ICITY SCHEDULES
Richardson, D.S., Hurlock, C., Hill, K., Newman, J., McKeag, N.,
Groves, L., Orchard, K.H. Southampton University Hospitals, South-
ampton, Hampshire, United Kingdom.
The outcome for patients with high-risk AML, particularly those
with leukaemia at the time of allogeneic transplant remains poor
even using full intensity conditioning. A recently published ap-
proach used pre-conditioning chemotherapy prior to the delivery
of a reduced intensity transplant schedule during the period of cyto-
penia. Initial results indicate feasibility and potential for long-term
disease control.
The bi-halogen purine analogue Clofarabine has significant ac-
tivity as a single agent in AML and is well tolerated. These charac-
teristics suggest Clofarabine is an ideal agent to use as pre-
conditioning therapy.
We have treated 5 patients with high-risk, refractory AML using
Clofarabine pre-conditioning to reduce disease burden before full
or reduced intensity allogeneic transplantation. In 4 patients, Clo-
farabine was administered as a single agent (40 mg/m2/day for 5
days) and in one, in combination with Cytarabine. 2 received re-
duced toxicity Busulphan-containing transplant schedules; 3 re-
ceived full intensity, TBI-based conditioning. The indications for
using Clofarabine in these patients, included severe allergy to Cy-
tarabine and heavy prior exposure to anthracycline. All 5 patientshad marrow involvement with AML prior to administration of Clo-
farabine. No unexpected toxicity was encountered and the extended
period of cytopenia compared with a conventional transplant was
manageable in this cohort. One patient who received a reduced in-
tensity regimen, was treated for VOD on the basis of clinical suspi-
cion but liver biopsy showed evidence of grade 3–4 haemosiderosis
only. 2 patients who received TBI suffered grade 3–4 mucositis and
required parenteral nutrition. All patients achieved .98% donor
chimerism at day 130. No patient experienced grade 3–4 acute
GvHD. 4 of 5 patients achieved substantial bulk reduction or erad-
ication of marrow AML infiltration following Clofarabine. The pa-
tient with Clofarabine-refractory disease achieved CR at day 30
following a full intensity transplant but has relapsed at 4 months
post transplant. One patient died in CR at 5 months post transplant
from pneumonitis. 3 patients are currently in CR at 2.5–21 months
follow up. The use of Clofarabine as a pre-conditioning agent prior
to the administration of the transplant conditioning schedule is well
tolerated with both full and reduced intensity protocols. This ap-
proach to allogeneic transplantation shows promise for the therapy
of patients with high risk, refractory AML.164
CLINICAL FEATURES OF ACUTE LEUKEMIA WITH CO-EXPRESSION OF
MYELOID AND LYMPHOID ANTIGENS
Jeong, S.H.1, Lee, H.W.1, Kang, S.Y.1, Cho, S.R.2, Park, J.S.1,
Choi, J.H.1, Kim, H.C.1 1Ajou University School of Medicine, Suwon,
Kyeong-Ki Do, Korea; 2Ajou University School of Medicine, Suwon,
Kyeong-Ki Do, Korea.
Background: Treatment of acute leukemias coexpressing mye-
loid and lymphoid antigens but does not meet the criteria for biphe-
notypic acute leukemia by EGIL is uncertain and its prognosis
unpredictable. We studied clinical outcomes of those acute leuke-
mia with coexpression. Method: Medical charts from 68 patients
diagnosed as coexpressing acute leukemia between Jan. 2000 and
Dec. 2006 in Ajou University Hospital were reviewed retrospec-
tively. 17/52 AML patients and 5/16 ALL patients received Hema-
topoietic stem cell transplantation. Significance was obtained by
two-tailed Student’s t-test and survival analyzed by Kaplan-Meier
method. Results: The median age for all acute leukemia was 42.5
year (15  83). Age, gender, LDH level and cytogenetics were
not different compared to those diagnosed as single lineage acute
leukemia at the same time. Forty eight % (16/33) of ALL and
30% (52/176) of AML patients co-expressed counterpart lineage
markers. CD19 (11%), CD7 (10%), CD22 (8%), CD5 (8%),
CD10 (1%) in AML and CD13 (42%), CD33 (33%), CD14 (3%)
in ALL were co-expressed. The co-expressed AML patients showed
tendency to short survival duration compared with pure AML pa-
tients (18.5 months vs. 24.1 months, p 5 0.069). Co-expressed
AML patients without stem cell transplantation showed shorter sur-
vival than pure AML patients (12.9 months vs. 21 months, p 5
0.014). However in AML who were transplanted, the survival ad-
vantage was abrogated (coexpressed vs pure AML; 30 months vs.
35 months, p 5 0.244). In ALL, survival duration of the co-ex-
pressed patients was not shorter than that of pure ALL (19.4 months
vs. 21 months) regardless of transplantation. Conclusion: AML pa-
tients with co-expression of lymphoid markers should be regarded
as a poor prognostic group and more aggressive treatment such as
transplantation should be considered. Further study on a larger
number of patients should be investigated regarding the appropriate
criteria for BAL and treatment.165
CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT AT DIAGNOSIS DOES
NOT ADVERSELY AFFECT THE OUTCOME OF HIGH-DOSE CHEMOTHER-
APY AND TRANSPLANT FOR PATIENTS WITH ACUTE MYELOID LEUKE-
MIA (AML)
Petropoulos, D.1, Giralt, S.A.2, Andersson, B.S.2, Chan, K.W.3,
Rondon, G.2, Popat, U.R.2, Hosing, C.2, Alousi, A.M.2,
Champlin, R.E.2, de Lima, M.J.2 1MD Anderson Cancer Center,
62 Poster Session IHouston, TX; 2MD Anderson Cancer Center, Houston, TX; 3Texas
Transplant Institute, San Antonio, TX.
Objective: To evaluate the impact of the presence of CNS disease
at diagnosis in the outcome of AML patients who underwent high-
dose chemotherapy and stem cell transplant. Methods: We per-
formed a retrospective study of all transplants performed for AML
in our institution between 1993 and 2007. Twenty-one patients
(11 males) with CNS disease were identified. Five had unclassified
AML, 2 M1, 2 M2, 9 M4 and 3 MDS. All but one patient had inter-
mediate or poor cytogenetics. Twelve patients were in remission (4
in CR1, 6 in CR2, 2 in greater CR) at the time of transplant. Four
patients had refractory relapse, 4 untreated relapse and one primary
induction failure. All patients were in CNS CR at the time of trans-
plant. Median age was 22.5 years (range 2–66). Three patients re-
ceived autologous graft. The conditioning regimen was
chemotherapy-based in 19 patients [Busulfan (Bu)-Fludarabine
(Flu): 6; Bu-Cyclophosphamide (Cy)-Thiotepa (TEP): 6; Flu-Mel-
phalan (Mel)-TEP: 2; Flu-Mel: 1; Flu-Mel-Mylotarg: 1; Bu-Cy: 1;
Decitabine-Bu-Cy:1; Cy-Etoposide:1]. Two patients received Flu-
Mel with TBI. GVHD prophylaxis was tacrolimus-based in 14/18
allogeneic transplants [with methotrexate (MTX) in 13 or steroids
in one], cyclosporine-based in 2 (one with MTX, one with steroids)
with 2 patients receiving T-cell depleted graft. The donor was
matched related in 9, matched unrelated in 4, mismatched related
in 4 and mismatched unrelated (cord) in 1. Eleven patients received
marrow, 9 PBSC and one cord blood transplant. Patients received
intrathecal chemotherapy monthly  6 months post-transplant as
CNS prophylaxis. Results: Twelve patients died (hemorrhage: 1,
sepsis: 2, acute GVHD: 2, MOF:1, chronic GVHD:1, relapse: 5).
With a median follow-up of 7.5 years, 9 patients are alive, 8 in
CCR, one in CR after CNS relapse and salvage chemotherapy.Con-
clusions: The presence of CNS disease at diagnosis should not pre-
clude the use of stem cell transplantation as treatment for AML.LYMPHOMA/MULTIPLE MYELOMA166
QUANTITATIVE MRD MONITORING IDENTIFIES DISTINCT GVL RE-
SPONSE PATTERNS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
FOR CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE GCLLSG
CLL3X TRIAL
Dreger, P.1, Boettcher, S.2, Stilgenbauer, S.3, Bunjes, D.3, Schubert, J.4,
Cohen, S.5, Hallek, M.6, Kneba, M.2, Dohner, H.3, Ritgen, M.2 1Uni-
versity of Heidelberg; 2University of Schleswig-Holstein, Kiel; 3Univer-
sity of Ulm; 4University of Saarland, Homburg, Germany; 5Hopital
Maisonneuve Rosemont, Montreal, Canada; 6University of Cologne,
Germany.
The purpose of this study was to prospectively analyse minimal
residual disease (MRD) kinetics after reduced-intensity allogeneic
stem cell transplantation (allo-SCT) in high-risk chronic lympho-
cytic leukemia (CLL). Subjects were the first 30 consecutive pa-
tients from a prospective disease-specific multicenter clinical trial
by the German CLL Study Group (study patients), and 7 pilot pa-
tients treated identically. All patients had an unfavorable VH muta-
tional status. Donor lymphocyte infusions (DLI) were administered
preemptively in case of incomplete chimerism and/or stable or in-
creasing MRD, provided that GVHD was absent after complete
withdrawal of immunosuppression.
Results: Using quantitative RQ-PCR and/or flow-based MRD
monitoring (sensitivity.510–4), four distinct patterns of MRD ki-
netics could be identified: (i) patients who achieved durable MRD
negativity without direct evidence of graft-versus-leukemia effects
(GVL; n 5 4); (ii) patients who showed a complete MRD response
to GVL (n5 18); (iii) patients who responded to GVL but failed to
reach complete MRD clearance (n 5 4); and (iv) patients in whom
a GVL effect with subsequent MRD suppression could not be in-
duced (n 5 2). Taking into account 2 non-relapse-related deaths,
study patients had a 54% probability of being alive and MRD-neg-
ative 12 months post transplant. MRD negativity occurring at this
time or later was durable in all cases except one. Three-year non-re-
lapse mortality, event-free, and overall survival of study patients was
11%, 58% and 71%, respectively. Conclusions: Effective GVL ac-tivity can be induced in most patients with high-risk CLL after allo-
SCT according to the design chosen here. GVL occurs essentially
in the context of chronic graft-versus-host disease induced by im-
munosuppression tapering or DLI. However, due to development
of secondary GVL resistance, in a signficant proportion of cases sus-
tained MRD negativity is not achieved.167
REDUCED INTENSITY VERSUS FULL MYELOABLATIVE STEM CELL
TRANSPLANT FOR ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA
Peres, E., Levine, J., Kato, K., Krijanovski, O., Khaled, Y., Ferrara, J.,
Yanik, G., Mineishi, S. University of Michigan, Ann Arbor, MI.
Background: Patients with CLL who are refractory to fludara-
bine have a median survival of 12 months. Reduced intensity condi-
tioning (RIC) for stem cell transplant may decrease transplant
related mortality (TRM) compared to full intensity conditioning
(FIC), but long term effectiveness is unclear. We compared out-
comes of 50 patients with advanced CLL who underwent allogeneic
hematopoietic stem cell transplant (HSCT) at the University of
Michigan with different intensity conditioning regimens.Methods:
Twenty one patients with CLL received RIC and 29 received FIC
prior to allogeneic HSCT between 1995 and 2005. RIC consisted
of Fludarabine (80–125 mg/m2) Busulfan (6.4 mg/kg IV or 8 mg/
kg oral) and Total lymphoid irradiation of 2–4 Gy. FIC consisted
of either CVB (cyclophosphamide 1800 mg/m2, etoposide 200
mg/m2 and BCNU 450 mg/m2) (n 5 20) or Bu/Cy (busulfan 3.2
mg/kg and cyclophosphamide 60 mg/kg for 2 days) (n 5 9). Graft
versus host disease prophylaxis consisted of tacrolimus and mycofe-
nolate mofetil in the RIC group and tacrolimus and methotrexate in
the FIC group. Results: The median age was 56 years (range 41–61
years) in the RIC group and 50 years (range 26–61 years) in the FIC
group. There was no difference between groups regarding the num-
ber of prior therapies or stem cell source. High risk cytogenetics
were present in 50% (11/21) of the RIC group and 68% (20/29)
(del 17q13 or del 11q22 or complex cytogenetics) in the FIC group.
The donor source consisted of matched unrelated (MUD) 62% (13/
29) in the RIC and 45% (9/20) in the FIC group. RIC recipients
were significantly more likely to be alive at all times post HSCT
(5 y OS RIC 63% versus FIC 18%, p 5 0.006). High TRM was
the primary cause of inferior survival in the FIC recipients who ex-
perienced double the day 100 TRM (FIC 27% versus RIC 14%, p5
0.005). The relapse rate was 14% regardless of conditioning regi-
men with the majority of relapses occurring after day 100. Likewise
the incidence of severe GVHD grade II-IV was similar in both
groups (FIC 27% versus RIC 28%). Conclusion: These data sug-
gest that RIC results in significant superior overall survival com-
pared to FIC in patients with CLL despite the higher proportion
of HLA-disparaty in the RIC group. The lower TRM in the RIC
group accounted for the major difference in overall survival.168
UNRELATED CORD BLOOD TRANSPLANTATION IN ADULTS WITH LYM-
PHOID MALIGNANCIES. A EUROCORD/EBMT-LYMPHOMA WORKING
PARTY STUDY
Rodrigues, C.A.1, Sanz, G.2, Brunstein, C.3, Renaud, M.4, Blaise, D.5,
Rio, B.6, Cairo, M.S.7, de Lima, M.8, Sureda, A.9, Wagner, J.3,
Gluckman, E.1, Rocha, V.1 1Eurocord Office, Hopital Saint Louis, Paris,
France; 2Hospital Universitario La Fe, Valencia, Spain; 3University of
Minnesota Medical School, Minneapolis, MN; 4Hopital La Miletrie,
Poitiers, France; 5 Institut Paoli Calmettes, Marseille, France; 6Hotel
Dieu, Paris, France; 7Columbia University, New York, NY; 8MD An-
derson Cancer Center, Houston, TX; 9Hospital Santa Creu i Sant Pau,
Barcelona, Spain.
Umbilical cord blood transplants (UCBT) from unrelated donors
is a feasible option for adults with high-risk acute leukemia. How-
ever, little is known about the outcome of UCBT in patients with
advanced lymphoid malignancies. We evaluated 104 adult patients
(median age, 41 years; range 16–65 years) who received a single
